On Wednesday’s episode of Mad Money, host Jim Cramer explained that if investors find an executive capable of pulling off a turnaround, they should stick with that leader for the long term.
“This morning, when the market was down, my colleagues at Squawk on the Street, David Faber and Carl Quintanilla, were questioning me about whether we just turn to the same old same old growth stocks when we bounce, and more important, why do we do so? I said it’s simple. These stocks, I’m speaking of things like the Magnificent Seven, have growth in a market that’s actually starved for growth. And growth is what saves you. Growth is what makes you money.”
READ ALSO: 8 Stocks Jim Cramer Was Asked About and 9 Latest Stocks on Jim Cramer’s Radar.
Faber then asked Cramer if it meant that there was nothing else catching Cramer’s attention. To which Cramer responded, “Absolutely not. I’m drawn to companies that are doing new things.” He noted how most CEOs are generally satisfied with maintaining their existing operations, making small adjustments, but rarely venturing into bold initiatives.
“So we end up defaulting to groups where the growth never seems to quit. The great build-out of huge warehouses filled with racks of supercomputers… There are more Larry Culps out there creating wealth away from tech. They’re just very darn hard to find. Now, I’m going to keep looking for them. But in the meantime, there’s nothing wrong with falling back on Big Tech and the Magnificent Seven, the only assured growth behemoths in the entire market.”
Our Methodology
For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on November 5. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the second quarter of 2025, which was taken from Insider Monkey’s database of over 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Jim Cramer’s Recent Thoughts on These 8 Stocks
8. CVS Health Corporation (NYSE:CVS)
Number of Hedge Fund Holders: 71
CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently shared thoughts on. Cramer discussed the company’s “reinvention,” as he said:
“Sadly, this tale of reinvention doesn’t happen very often, but when it does, I celebrate it. For example, I really like what David Joyner’s doing with the turnaround at CVS. Value creation, there’s major covering the front and back of the store, along with the incredible comeback in health insurance.”
CVS Health Corporation (NYSE:CVS) provides healthcare solutions through insurance, pharmacy benefit management, and retail pharmacy services. During the August 28 episode, when a caller inquired about Cigna stock, Cramer suggested CVS Health Corporation (NYSE:CVS) instead, as he commented:
“I’m going to take a big, big monster pass on Cigna and suggest that you pull down some CVS. Yes, because I think that the old Consumer Value Stores, by the way, I think CVS is crushing it. And I think this guy David Joyner, you know, mi casa es su casa, David Joyner, what does that really mean? It sounds good.”
7. GE Aerospace (NYSE:GE)
Number of Hedge Fund Holders: 100
GE Aerospace (NYSE:GE) is one of the stocks Jim Cramer recently shared thoughts on. Cramer praised the CEO, Larry Culp, during the episode, as he remarked:
“I’m drawn to companies that are doing new things, innovating, improving, but most companies just aren’t doing that. I’m drawn to companies like the one Larry Culp re-invented, the old General Electric, now GE Aerospace. He led an amazing turn, and it produced bountiful gains for anyone who believed. It made you a huge amount of money, a life changer for all who got a piece of it…
What Larry created here, the three huge businesses that could have been, well, nothing if he hadn’t taken drastic action is testament to what you can do if you’re a thoughtful, hardworking, driven, big thinker like Larry… who saved one of the most storied companies on earth that was teetering on the precipice when he was, when he got there.”
GE Aerospace (NYSE:GE) develops and produces aircraft engines, components, and power systems for commercial and defense use. The company also provides engine maintenance, repair, and overhaul services.
6. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 119
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented:
“I do believe that there are very few biotechs that I really want to buy right now because they’re so picked over. Look, in the end, there’s Eli Lilly and there’s everybody else.”
Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions. Cramer discussed the stock during the October 30 episode and highlighted its solid GLP-1 revenue, as he said:
“Or how about the drug companies? Holy cow, remember them? They used to be big and important, weren’t they? Eli Lilly reported this morning, and their GLP-1 complex, you know, the weight loss diabetes thing, made a billion dollars more than Wall Street expected. That’s tech-like. When I first saw it, I was thinking, okay, the market won’t care. Big yawner. We own Lilly for the trust, we believe in it, but we feel like we’re dopes lately.
But you know what? I knew that Dave Ricks, the CEO, was going to be on Squawk on the Street. I said, hey, listen, maybe something good will happen here… maybe, I’m too jaded, right? I just assumed nobody will care because it’s pharma, a group that nobody seems to want in this environment. Apparently, I was wrong. That’s right. Eli Lilly’s stock rallied nearly 4% today. I think we have Meta’s weakness to thank for that gain.”
5. Bristol-Myers Squibb Company (NYSE:BMY)
Number of Hedge Fund Holders: 67
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer showed his disappointment in the company’s schizophrenia medicine sales, as he commented:
“Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not selling well at all.”
Bristol-Myers Squibb Company (NYSE:BMY) develops biopharmaceutical products for cancer, cardiovascular, autoimmune, and neurological diseases. During the September 26 episode, when a caller asked if they should add to their position in the company’s stock, Cramer replied:
“Well… I have said, and I’ve been abject about it, that I think I might be wrong in Bristol. That’s why I’ve not added to it. J&J is doing a better job than Bristol, and it’s rankling me. Let’s listen to J&J. We’re not afraid to take a loss if we have to, but we’re not giving up yet.”
4. Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund Holders: 62
Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as he remarked:
“Look, I think Amgen needs to do something because they’ve gotta broaden the portfolio where they need to be able to tell a little bit better story about some of the things that, they have a lot of good medicines, and they had a really good quarter last night.”
Amgen Inc. (NASDAQ:AMGN) manufactures human therapeutics for cancer, cardiovascular, inflammatory, and bone disorders. Its main products include Enbrel, Prolia, Repatha, Otezla, and Kyprolis. Cramer mentioned the company during the June 25 episode and said:
“Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly when it comes to injections any day… So what did we learn when Amgen presented on Monday afternoon? First, the market didn’t like it. The stock sold off. Hard response… There… [was] some genuinely new information too. I’m talking about the Phase 1 trial, data from the separate trial, studying much lower starting doses of MariTide with different escalation schedules, far less vomiting at the low doses…
This is really important because it seems to go down easier when patients start at a lower dose and then ratchet up gradually. So what exactly does this mean for Amgen, the stock? Again, Wall Street was not impressed. When Amgen published this data on Monday afternoon, the stock dropped an incredible 15 points in just a few minutes, finishing the day down almost 6%. But over the past two days, the stock’s recovered a big chunk of the ground that was lost, so maybe there’s something good here…
My bigger concern, we may not see MariTide get FDA approval and make it to the market until late 2027 at best… Amgen’s very confident that their Phase 3 trial will be successful by the time 2027 comes along. Millions of people will probably be taking that Lily weight loss pill. That said, the stock… sold off to the point where I would not bet against it…
I don’t think that new MariTide data is bad enough to justify this decline. And now you’re getting a bargain. That’s right, Amgen’s at a bargain, basement price of 13 times earnings…. And while Lilly’s a great stock that certainly deserves a premium… I think Amgen’s gotten too cheap by comparison.
This is still a big biotech company with mid-single-digit earnings growth expected this year, not to mention potential upside for this GLP-1 drug down the road. But here’s the bottom line: We got plenty of data from this American Diabetes Association conference that ended earlier this week, and I think Amgen’s trial results were misunderstood. The stock did not deserve to get hit this hard. Lily’s still my favorite way to play the GLP-1 story. But if you’re looking for a bargain, you could do a lot worse than Amgen.”
3. Apple Inc. (NASDAQ:AAPL)
Number of Hedge Fund Holders: 156
Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said companies like Apple are “nation-states,” as he remarked:
“Apple, I think, is going to have a great quarter. So I think that their PE is probably going to be roughly just a little bit above the market multiple. All these companies are actually very big conglomerates… I like the companies for what they have, which is different businesses that are firing all cylinders… In the end, these are the best companies in the world. They’re nation-states with good balance sheets. They’re not momentum plays.”
Apple Inc. (NASDAQ:AAPL) sells smartphones, computers, tablets, wearables, and accessories under brands like iPhone, Mac, iPad, and Apple Watch. During the November 3 episode, Cramer discussed how the company can acquire AI. He commented:
“Apple’s looking better and better because they opted out. They’re not trying to build the best chatbot, though they are working on improvements to Siri that should arrive by next spring… But overall, as far as I can see, this strategy is to do the same thing they did with search. Why not just let somebody else build it and then pay Apple for the privilege of being the default on all their devices?
Google reportedly pays them $20 billion per year to be the go-to search engine, which we now know was held up in court as a payment that was totally legit. I bet they can even get more for that from one of the hyperscalers that wants to be the go-to generative AI platform. There’s not that much difference between them. It would really help if they had Apple. At times, over the past couple years, Apple’s come under fire for not really seeming to have an AI strategy.
But as I said repeatedly, they don’t need one because they have an installed base of over 2.35 billion active devices, and any of the hyperscalers would happily pay up for access to that user base. Still one more reason why I always say Apple, own it, don’t trade it. Doesn’t hurt that these guys reported a magnificent quarter. Yet the stock ultimately didn’t get much credit for it, but it did run up in advance of the report.”
2. McDonald’s Corporation (NYSE:MCD)
Number of Hedge Fund Holders: 78
McDonald’s Corporation (NYSE:MCD) is one of the stocks Jim Cramer recently shared thoughts on. Cramer noted the company cutting prices on its products. He said:
“Or how about a stock like McDonald’s? Headlines come out this morning, they say it’s a big disappointment, a huge disappointment. It was a big miss on revenues, big miss on earnings, red ink. Well, it made it look like the stock had to go lower, right? But what if the red ink is wrong? What if it was just one more trick of the index sellers? All restaurants have been challenged during this period. What matters is how they respond to the darn challenge. McDonald’s, unlike so many other chains that lack the scale and the strength, is lowering prices, lowering them dramatically, and it’s working. The other guys keep hoping customers will just get wealthier, come back. They don’t want to admit that they’re taking prices way too high to levels where the consumer’s too cash-strapped to afford them because they didn’t want to miss their quarter, and they’re missing their quarters big now. That’s what we were looking at. I said before the market open, you gotta buy McDonald’s, because it understands what our customers in our country and the world are going through right now. There’s been too much inflation. So what they did, they cut prices. That’s what they did. And even though the market was bad, this stock finished up big. Why? Because the next quarter’s got the $5 sausage, egg, and cheese McMuffin, coffee, and a tater. That’s like the old days, five bucks. That’s what matters.”
McDonald’s Corporation (NYSE:MCD) operates and franchises restaurants that provide burgers, chicken sandwiches, fries, beverages, and desserts.
1. Shopify Inc. (NASDAQ:SHOP)
Number of Hedge Fund Holders: 69
Shopify Inc. (NASDAQ:SHOP) is one of the stocks Jim Cramer recently shared thoughts on. Cramer discussed the stock’s recent decline, as he commented:
“How about a stock like Shopify? I picked this one, this internet behind-the-scenes player, because I’ve done the homework, that’s why. More specifically, I was able to get into this market’s kitchen and see how the sausage was made, and I didn’t like it. Shopify’s a big company, and its stock, like so many others, trades with the futures even though it’s Canadian. That’s why the stock started going down hard. It was just right in line with Palantir, as if there was something truly wrong with this company.
The cash flow, the sales, the earnings, the outlook, these are the kinds of things that I’m asking the company’s president, Harley Finkelstein, while he is on Squawk on the Street. I’m interviewing why the stock’s in free fall. I recall, six months ago, the exact same objections, the exact same pack of lies. I said, don’t believe them. It was at 100 bucks, stock’s up 60 since then. It was a bogus rap then and a bogus rap now. Harley’s expecting a very strong holiday season despite what you might’ve read in… any press story. See, it was time to buy Shopify, not sell it.”
Shopify Inc. (NASDAQ:SHOP) provides a commerce platform that helps businesses manage products, orders, payments, and customer relationships.
While we acknowledge the potential of Shopify Inc. (NASDAQ:SHOP) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SHOP and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
